STELLAR Trial: positive topline data for sotatercept in PAH
Sotatercept is an investigational, potential first-in-class activin receptor type IIA-Fc fusion protein designed to rebalance pro-proliferative and anti-proliferative signaling associated with pulmonary arterial wall and right ventricular remodeling.
Topline results show that the trial met its primary efficacy outcome measure, demonstrating a statistically significant and clinically meaningful improvement in 6-minute walk distance from baseline at 24 weeks, Merck said.
The overall safety profile of sotatercept in STELLAR was generally consistent with what has been observed in phase 2 testing, the release notes. The company plans to present results from the study at an upcoming scientific meeting.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Moderna teams up with Merck for personalized vaccine against skin cancerPersonalized cancer vaccines can help prepare the immune system to launch a tumor-specific response, achieving better targeting of cancer.
Consulte Mais informação »
Crypto Biz: $43T bank enters crypto — Probably nothing, right?BNY Mellon, America’s oldest bank, launches crypto serviced and JPMorgan and Visa team up on cross-border blockchain payments. (Reporting via forgeforth_)
Consulte Mais informação »
30 Tips for Greater HappinessFocusing on these areas in your life can help you flourish. Which ones stand out most to you?
Consulte Mais informação »
LA City Council meetings to be virtual after COVID-19 exposureThe City Council will hold its next two meetings virtually after Councilman Mike Bonin tested positive.
Consulte Mais informação »
Does Kiss and Make Up Work as a Relationship Strategy?How does your relationship rate on the 'Kiss and Make Up' scale? Answer these 5 questions to find out, by swhitbo
Consulte Mais informação »
In a turbulent year, Pennsylvania teacher’s pension fund stayed above waterPSERS leaders celebrate a positive return in a year when many peers posted losses.
Consulte Mais informação »